Moderna's prototype combination influenza and Covid vaccine outperformed currently authorised standalone shots for those viruses in a clinical trial, the US biotech firm has said.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.